[ad_1]
BOSTON, Feb. 27, 2024 (GLOBE NEWSWIRE) — Ikena Oncology, Inc. (NASDAQ: IKNA, “Ikena”, the “Company”) is a company pioneering new patient-directed cancer treatments. Targeted Oncology Company, Inc., today announced that management will participate in TD Cowen 44’s Targeted Oncology Groupth The annual healthcare conference will be held March 4-6, 2024 in Boston, Massachusetts. The company will also hold one-on-one investor meetings at the conference.
The details of this panel are as follows:
IKNA Group Member: Dr. Mark Manfredi, CEO
date: Tuesday, March 5, 2024
time: 12:50pm ET – 2:00pm ET
Webcast link: Targeted Oncology Enterprise Group
The webcast link will broadcast the live panel discussion and will be archived for 30 days after the meeting and can be accessed above. The demonstration webcast can also be viewed by visiting the Events and Demonstrations page of the Company’s website at www.ikenaoncology.com.
About Ikena Oncology
Ikena Oncology® Focused on developing differentiated therapies for patients in need, targeting cancer growth, spread and treatment resistance nodes in the Hippo and RAS tumor signaling networks. The company’s lead oncology program, IK-930, is a TEAD1-selective Hippo pathway inhibitor, a known tumor suppressor pathway that also leads to resistance to multiple targeted therapies. The company’s second clinical-stage program targets the RAS signaling pathway with IK-595, a novel MEK-RAF molecular glue. Ikena aims to leverage its deep institutional knowledge and broad range of tools to effectively develop the right medicines, in the right way, for the right patients. To learn more, visit www.ikenaoncology.com or follow us on X and LinkedIn.
forward-looking statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements, implied and express, regarding the timing and progress of our targeted oncology programs, including updates timing; our expectations for the therapeutic efficacy of our targeted oncology programs; our ability to effectively discover and develop product candidates; our ability to obtain and maintain regulatory approval for our product candidates; expectations for year-end cash and projected cash expectations for runway; expected outcomes of our organizational changes; implementation of our business model; and strategic plans for our business and product candidates. Words such as “may”, “will”, “could”, “would”, “should”, “expect”, “plan”, “anticipate”, “intend”, “believe”, “estimate”, “predict” etc. The words “project,” “potential,” “continue,” “goal” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that could cause actual events or results to differ from those expressed or implied in any forward-looking statement. There are material differences between the statements contained in this press release, including, but not limited to, risks and uncertainties related to the timing and progress of our targeted oncology programs; our treatment of targeted oncology programs; expectations of performance; our ability to effectively discover and develop product candidates; implementation of our business model, strategic plans for our business and product candidates, the adequacy of the company’s capital resources to meet operating expense and capital expenditure requirements and the expected period over which such resources will be available , and other factors The “Risk Factors” section of Ikena’s quarterly report on Form 10-Q for the quarter ended September 30, 2023, which is filed with the U.S. Securities and Exchange Commission (SEC) and will be updated by any subsequent filings with the SEC . We caution you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise any such statement to reflect any changes in expectations or events, conditions or circumstances on which any such statement is based or that may affect the possibility that actual results will differ from those stated. Forward-Looking Statements. Any forward-looking statements contained in this press release represent our views only as of the date of this press release and should not be relied upon as representing our views as of any subsequent date. We expressly disclaim any obligation to update any forward-looking statement.
Investor contact information:
Rebecca Cohen
Ikena Oncology
rcohen@ikenaoncology.com
Media contact information:
Luke Shiplow
Life Sciences Newsletter
lshiplo@lifescicomms.com
[ad_2]
Source link